Literature DB >> 17508274

Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors.

Janice L Berliner1, Angela Musial Fay.   

Abstract

These cancer genetic counseling recommendations describe the medical, psychosocial and ethical implications of identifying at-risk individuals for hereditary breast and ovarian cancer (HBOC) through cancer risk assessment, with or without genetic susceptibility testing. They were developed by members of the Practice Issues Subcommittee of the National Society of Genetic Counselors' Familial Cancer Risk Counseling Special Interest Group. The information contained in this document is derived from extensive review of the current literature on cancer genetic risk assessment as well as the professional expertise of genetic counselors with significant experience in education and counseling regarding hereditary breast and ovarian cancer. Critical components of the process include the ascertainment of medical and family histories, determination and communication of cancer risk, assessment of risk perception, education regarding the genetics of HBOC, discussion of molecular testing for HBOC if appropriate (including benefits, risks and limitations) and any necessary follow-up. These recommendations do not dictate an exclusive course of management or guarantee a specific outcome. Moreover, they do not replace the professional judgment of a health care provider based on the clinical situation of a client.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17508274     DOI: 10.1007/s10897-007-9090-7

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.717


  94 in total

1.  Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families.

Authors:  N D Kauff; P Perez-Segura; M E Robson; L Scheuer; B Siegel; A Schluger; B Rapaport; T S Frank; K Nafa; N A Ellis; G Parmigiani; K Offit
Journal:  J Med Genet       Date:  2002-08       Impact factor: 6.318

2.  Assessing BRCA carrier probabilities in extended families.

Authors:  Carlos H Barcenas; G M Monawar Hosain; Banu Arun; Jihong Zong; Xiaojun Zhou; Jianfang Chen; Jill M Cortada; Gordon B Mills; Gail E Tomlinson; Alexander R Miller; Louise C Strong; Christopher I Amos
Journal:  J Clin Oncol       Date:  2006-01-20       Impact factor: 44.544

3.  Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.

Authors:  Sylvia K Plevritis; Allison W Kurian; Bronislava M Sigal; Bruce L Daniel; Debra M Ikeda; Frank E Stockdale; Alan M Garber
Journal:  JAMA       Date:  2006-05-24       Impact factor: 56.272

4.  Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

Authors:  M C King; S Wieand; K Hale; M Lee; T Walsh; K Owens; J Tait; L Ford; B K Dunn; J Costantino; L Wickerham; N Wolmark; B Fisher
Journal:  JAMA       Date:  2001-11-14       Impact factor: 56.272

5.  Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.

Authors: 
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

6.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.

Authors:  F J Couch; M L DeShano; M A Blackwood; K Calzone; J Stopfer; L Campeau; A Ganguly; T Rebbeck; B L Weber
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

Review 7.  Application of breast cancer risk prediction models in clinical practice.

Authors:  Susan M Domchek; Andrea Eisen; Kathleen Calzone; Jill Stopfer; Anne Blackwood; Barbara L Weber
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

8.  Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.

Authors:  Susan M Domchek; Tara M Friebel; Susan L Neuhausen; Theresa Wagner; Gareth Evans; Claudine Isaacs; Judy E Garber; Mary B Daly; Rosalind Eeles; Ellen Matloff; Gail E Tomlinson; Laura Van't Veer; Henry T Lynch; Olufunmilayo I Olopade; Barbara L Weber; Timothy R Rebbeck
Journal:  Lancet Oncol       Date:  2006-03       Impact factor: 41.316

9.  Accuracy of family cancer history in breast cancer patients.

Authors:  B Theis; N Boyd; G Lockwood; D Tritchler
Journal:  Eur J Cancer Prev       Date:  1994-07       Impact factor: 2.497

10.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Authors:  Timothy R Rebbeck; Tara Friebel; Henry T Lynch; Susan L Neuhausen; Laura van 't Veer; Judy E Garber; Gareth R Evans; Steven A Narod; Claudine Isaacs; Ellen Matloff; Mary B Daly; Olufunmilayo I Olopade; Barbara L Weber
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

View more
  74 in total

1.  Genetic counselor opinions of, and experiences with telephone communication of BRCA1/2 test results.

Authors:  A R Bradbury; L Patrick-Miller; D Fetzer; B Egleston; S A Cummings; A Forman; L Bealin; C Peterson; M Corbman; J O'Connell; M B Daly
Journal:  Clin Genet       Date:  2010-10-12       Impact factor: 4.438

2.  Predictive Genetic Testing and Alternatives to Face to Face Results Disclosure: A Retrospective Review of Patients Preference for Alternative Modes of BRCA 1 and 2 Results Disclosure in the Republic of Ireland.

Authors:  Rosie O'Shea; Marie Meany; Cliona Carroll; Nuala Cody; David Healy; Andrew Green; Sally Ann Lynch
Journal:  J Genet Couns       Date:  2015-09-26       Impact factor: 2.537

3.  Personal genomics services: whose genomes?

Authors:  David Gurwitz; Yael Bregman-Eschet
Journal:  Eur J Hum Genet       Date:  2009-03-04       Impact factor: 4.246

4.  Retrospective comparison of patient outcomes after in-person and telephone results disclosure counseling for BRCA1/2 genetic testing.

Authors:  Courtney Doughty Rice; Jennifer Gamm Ruschman; Lisa J Martin; Jennifer B Manders; Erin Miller
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

5.  Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: comparison with control population.

Authors:  Michel Dorval; Karine Bouchard; Elizabeth Maunsell; Marie Plante; Jocelyne Chiquette; Stéphanie Camden; Michel J Dugas; Jacques Simard
Journal:  J Genet Couns       Date:  2008-05-15       Impact factor: 2.537

6.  Five skills psychiatrists should have in order to provide patients with optimal ethical care.

Authors:  Edmund Howe
Journal:  Innov Clin Neurosci       Date:  2011-03

Review 7.  Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Authors:  Tuya Pal; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

8.  Development and validation of a primary care-based family health history and decision support program (MeTree).

Authors:  Lori A Orlando; Adam H Buchanan; Susan E Hahn; Carol A Christianson; Karen P Powell; Celette Sugg Skinner; Blair Chesnut; Colette Blach; Barbara Due; Geoffrey S Ginsburg; Vincent C Henrich
Journal:  N C Med J       Date:  2013 Jul-Aug

9.  BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.

Authors:  Alexis D Bakos; Sadie P Hutson; Jennifer T Loud; June A Peters; Ruthann M Giusti; Mark H Greene
Journal:  Health Expect       Date:  2008-09       Impact factor: 3.377

10.  "Would you test your children without their consent?" and other sticky dilemmas in the field of cancer genetic testing.

Authors:  Karina L Brierley; Danielle C Bonadies; Anne Moyer; Ellen T Matloff
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.